Processa Pharmaceuticals / GlobeNewswire · Jul 2025
Confirmed the Intact option remained a key strategic partnership and reiterated the potential milestone and royalty economics.
Smart gels for local drug delivery to the gut
Company research
Public company, workplace, funding, and market signals
Overview
Clinical-stage biopharmaceutical company developing localized GI drug-delivery therapies built around a thermosensitive hydrogel / smart-gel platform to improve retention, local concentration, and reduce systemic exposure.
Primary product
INT-102 thermosensitive hydrogel (smart-gel) platform for localized GI drug delivery
Founded
2015
Headquarters
2627 Hanover Street, Palo Alto, CA 94304, United States
Team size
1-10
Industry
Pharmaceutical Manufacturing
Sub-industry
Biopharmaceuticals; drug delivery
Offices
2627 Hanover Street, Palo Alto, CA 94304, United States
740 Broadway Street, Redwood City, CA 94063, United States
640 Masonic Way Suite 5204, Belmont, CA 94002, United States
Business model
clinical-stage drug development
therapeutics licensing
grant-funded R&D
Funding
Stage
clinical-stage; grant-supported and venture-backed
Total raised
$4.7M
Latest round
Grant · May 2024
People & investors
Leadership
CEO & Co-Founder
Founder & Scientific Advisor
Lorin K. Johnson, PhD
Board Member & Scientific Advisor
Work & culture
Product & market
Pricing
not publicly disclosed; likely drug-development and licensing economics
Differentiators
- —thermosensitive material becomes viscous/mucoadhesive at body temperature
- —localized delivery designed to increase drug concentration at the disease site
- —intended to reduce systemic exposure and side effects
- —improves retention compared with traditional topical GI formulations
- —platform can support multiple GI indications
Technology
thermosensitive hydrogel
mucoadhesive gel
localized GI drug delivery
Pregnane X Receptor (PXR) agonist formulation
5-HT4 receptor agonist PCS12852
mesalamine-based topical formulation
topical delivery platform for ulcerative colitis and GI bleeding
Customers
patients with ulcerative colitis
patients with gastrointestinal motility disorders
patients with upper gastrointestinal bleeding
clinicians and GI specialists
Competitors
systemic IBD/UC therapies
traditional enemas, foams, and suppositories
gastroparesis drug developers
other GI drug-delivery platform companies
Scale & contact
Latest news
Processa Pharmaceuticals / GlobeNewswire · Jun 2025
Announced Intact’s exclusive option to license PCS12852 for gastroparesis and other GI motility disorders; the deal included near-term cash, milestones, royalties, and an equity stake in Intact.
BioSpace · Jun 2025
Republished the deal announcement and summarized the potential economics and the phase 2 gastroparesis asset.
Benzinga · Jun 2025
Market reaction piece covering Processa’s stock move after the Intact licensing announcement.
Jobs and careers at Intact Therapeutics
0 jobs at Intact Therapeutics
No open positions
Check back later for new openings